Detail akcie Cogent Bioscis Rg online

Business Summary: Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3K?. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Cogent Biosciences Inc revenues was not reported. Net loss applicable to common stockholders increased 15% to $201.3M. Higher net loss reflects Research and development - Balancing va increase of 9% to $134M (expense), Labor & Related Expenses in R&D increase of 31% to $44.6M (expense), General and administrative - Balancing increase of 58% to $24.9M (expense).